Navigation Links
DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop
Date:8/26/2009

The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.

Horsham, PA (Vocus) August 26, 2009 -- The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.

Progression-Free Survival (PFS) endpoints are increasingly used for evaluation and approval of oncology drugs. Representatives from FDA, the National Cancer Institute (NCI), and PhRMA will present their perspectives on clinical, radiological, and statistical evaluation of progression-free survival. Sessions will include:

 
  • Clinical Assessment of Progression-Free Survival (PFS)
  • Radiological Evaluation of Progression-Free Survival (PFS)
  • Criteria for Determination of Progression
  • Statistical Evaluation of Progression-Free Survival- Role and Design of Independent Review
  • Statistical Evaluation of Progression-Free Survival--Handling Missing/Censored Observations
  • Statistical Evaluation of Progression-Free Survival--Analysis of Progression-Free Survival
  • Regulatory Considerations
Richard Pazdur, MD, Director, Office of Oncology Drug Products, CDER, FDA, will deliver the keynote address. In addition to his experience as a regulatory expert at FDA, Dr. Pazdur has distinguished himself in clinical and academic oncology. Click here for complete bio.

In addition, two tutorials will be held on October 7:

 
  • Time to Event Analysis for Non-Statisticians
  • Statistical Methods for Interval Censored Data Analyses
Click here to register for the Progression-Free Survival Oncology Workshop.

About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

Contact:
Joe Krasowski
DIA
+1-215-293-5812

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2796274.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
2. Advanced lung cancer patients see improved, progression-free survival
3. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
4. Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia
5. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
6. Survival differences by race most apparent in advanced stages of breast cancer
7. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Mediterranean Diet May Boost Alzheimers Survival
10. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
11. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: